Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines

Cancer Letters

Volumn 218, Issue 2, 2005, Pages 163-170

  Huguenin, Sandra ^a   Vacherot, Francis ^a   Fleury Feith, Jocelyne ^a,b   Riffaud, Jean Pierre ^c   Chopin, Dominique K ^a   Bolla, Manlio ^c   Jaurand, Marie Claude ^a  

^a INSERM   (France)

^b HÔPITAL TENON   (France)

^c NicOx SA   (France)

Author keywords

Apoptosis; Bladder carcinoma; Cell cycle; Nitric oxide; NO NSAIDs; Prostate cancer

Indexed keywords

1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 ACETIC ACID 3 (NITROOXYMETHYL)PHENYL ESTER; 2 (ACETYLOXY)BENZOIC ACID 4 (NITROOXYMETHYL)PHENYL ESTER; 2 FLUORO ALPHA METHYL (1,1' BIPHENYL) 4 ACETIC ACID 4 (NITROOXY)BUTYL ESTER; 3 [4 (2 ACETYLOXYBENZOYLOXY) 3 METHOXYPHENYL] 2 PROPENOIC ACID 4 (NITROOXY)BUTYL ESTER; 3 [4 [2 FLUORO ALPHA METHYL (1,1' BIPHENYL) 4 ACETYLOXY] 3 METHOXYPHENYL] 2 PROPENOIC ACID 4 (NITROOXY)BUTYL ESTER; 4 HYDROXY 2 METHYL N 2 PYRIDINYL 2H 1,2 BENZOTHIAZINE 3 CARBOXAMIDE 1,1 DIOXIDE NITRATE; 5 FLUORO 2 METHYL 1 [[4 (METHYLSULFINYL)PHENYL]METHYLENE] 1H INDEN 3 ACETIC ACID 4 (NITROOXY)BUTYL ESTER; 5 FLUORO 2 METHYL 1 [[4 (METHYLSULFINYL)PHENYL]METHYLENE] 1H INDEN 3 ACETIC ACID 6 (NITROOXYMETHYL) 2 METHYLPYRIDYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; ACRYLIC ACID DERIVATIVE; ALPHA METHYL 4 (2 METHYLPROPYL)BENZENE ACETIC ACID 2 METHOXY 4 [3 [4 (NITROOXY)BUTYLOXY] 3 OXO 1 PROPENYL]PHENYL ESTER; AMIDE; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; FLURBIPROFEN 4 NITROXYBUTYL ESTER; IBUPROFEN DERIVATIVE; INDOLE DERIVATIVE; INDOMETACIN DERIVATIVE; NCX 1102; NCX 1105; NCX 1301; NCX 2210; NCX 2216; NCX 2219; NCX 4040; NCX 530; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; URINARY TRACT CANCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MALE; NITRIC OXIDE DONORS; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY BLADDER NEOPLASMS;

EID: 12844260182     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.06.003     Document Type: Article

References (31)

1. J.L. Wallace, and P.D. Soldato The therapeutic potential of NO-NSAIDs Fundam. Clin. Pharmacol. 17 2003 11 20
2. J.L. Wallace, B. Reuter, C. Cicala, W. McKnight, M.B. Grisham, and G. Cirino Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat Gastroenterology 107 1994 173 179
3. C.K. Fujihara, D.M. Malheiros, J.L. Donato, A. Poli, G. De Nucci, and R. Zatz Nitroflurbiprofen, a new nonsteroidal anti-inflammatory, ameliorates structural injury in the remnant kidney Am. J. Physiol. 274 1998 F573 F579
4. W.K. MacNaughton, G. Cirino, and J.L. Wallace Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach Life Sci. 45 1989 1869 1876
5. V. Umansky, and V. Schirrmacher Nitric oxide-induced apoptosis in tumor cells Adv. Cancer Res. 82 2001 107 131
6. D.A. Wink, Y. Vodovotz, J. Laval, F. Laval, M.W. Dewhirst, and J.B. Mitchell The multifaceted roles of nitric oxide in cancer Carcinogenesis 19 1998 711 721
7. J.L. Williams, S. Borgo, I. Hasan, E. Castillo, F. Traganos, and B. Rigas Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention Cancer Res. 61 2001 3285 3289
8. K. Kashfi, Y. Ryann, L.L. Qiao, J.L. Williams, J. Chen, and P. Del Soldato Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect J. Pharmacol. Exp. Ther. 303 2002 1273 1282
9. A. Tesei, L. Ricotti, P. Ulivi, L. Medri, D. Amadori, and W. Zoli NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines Int. J. Oncol. 22 2003 1297 1302
10. A.W. Bak, W. McKnight, P. Li, P. Del Soldato, A. Calignano, G. Cirino, and J.L. Wallace Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma Life Sci. 62 1998 367 373
11. J.L. Williams, K. Kashfi, N. Ouyang, P. del Soldato, L. Kopelovich, and B. Rigas NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice Biochem. Biophys. Res. Commun. 313 2004 784 788
12. R.S. Pruthi, E. Derksen, and K. Gaston Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review J. Urol. 169 2003 2352 2359
13. H. Fujita, K. Koshida, E.T. Keller, Y. Takahashi, T. Yoshimito, M. Namiki, and A. Mizokami Cyclooxygenase-2 promotes prostate cancer progression Prostate 53 2002 232 240
14. M. Komhoff, Y. Guan, H.W. Shappell, L. Davis, G. Jack, and Y. Shyr Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas Am. J. Pathol. 157 2000 29 35
15. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
16. M.J. Thun, S.J. Henley, and C. Patrono Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J. Natl Cancer Inst. 94 2002 252 266
17. M. Oshima, J.E. Dinchuk, S.L. Kargman, H. Oshima, B. Hancock, and E. Kwong Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809
18. A.L. Sabichi, and S.M. Lippman COX-2 inhibitors and other NSAIDs in bladder and prostate cancer Prog. Exp. Tumor Res. 37 2003 163 178
19. M. Segasothy, S.A. Samad, A. Zulfigar, and W.M. Bennett Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic Am. J. Kidney Dis. 24 1994 17 24
20. M.M. Wolfe, D.R. Lichtenstein, and G. Singh Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N. Engl. J. Med. 340 1999 1888 1899
21. J.E. Keeble, and P.K. Moore Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs Br. J. Pharmacol. 137 2002 295 310
22. C. Lavagna, J.L. Burgaud, P. Del Soldato, and P. Rampal Antiproliferative effects of nitrosulindac on human colon adenocarcinoma cell lines Biochem. Biophys. Res. Commun. 284 2001 808 816
23. S. Fiorucci, L. Santucci, P. Gresele, R.M. Faccino, P. Del Soldato, and A. Morelli Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study Gastroenterology 124 2003 600 607
24. B. Rigas, and J.L. Williams NO-releasing NSAIDs and colon cancer chemoprevention: a promising novel approach (Review) Int. J. Oncol. 20 2002 885 890
25. K.V. Rao, C.J. Detrisac, V.E. Steele, E.T. Hawk, G.J. Kelloff, and D.L. McCormick Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder Carcinogenesis 17 1996 1435 1438
26. G.A. Piazza, W.J. Thompson, R. Pamukcu, H.W. Alila, C.M. Whitehead, and L. Liu Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis Cancer Res. 61 2001 3961 3968
27. J.T. Lim, G.A. Piazza, E.K. Han, T.M. Delohery, H. Li, and T.S. Finn Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines Biochem. Pharmacol. 58 1999 1097 1107
28. E.T. Goluboff, A. Shabsigh, J.A. Saidi, I.B. Weinstein, N. Mitra, and D. Heitjan Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis Urology 53 1999 440 445
29. G.A. Piazza, A.L. Rahm, M. Krutzsch, G. Sperl, N.S. Paranka, and P.H. Gross Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis Cancer Res. 55 1995 3110 3116
30. N. Nath, K. Kashfi, J. Chen, and B. Rigas Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association Proc. Natl Acad. Sci. USA 100 2003 12584 12589
31. J.L. Williams, N. Nath, J. Chen, T.R. Hundley, J. Gao, and L. Kopelovich Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention Cancer Res. 63 2003 7613 7618